New insider activity at Ocular Therapeutix ( (OCUL) ) has taken place on August 27, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Ocular Therapeutix stock, several key executives have made significant sales. Sanjay Nayak, the Chief Strategy Officer, sold 1,885 shares for a total of $22,695. Pravin Dugel, who serves as the Executive Chairman, President, and CEO, sold 21,494 shares, amounting to $258,787. Peter Kaiser, the Chief Development Officer, parted with 3,011 shares, generating $36,252. Additionally, Chief Scientific Officer Jeffrey S. Heier sold 3,063 shares, bringing in $36,878.
Recent Updates on OCUL stock
Ocular Therapeutix has recently received FDA agreement on a Special Protocol Assessment for its AXPAXLI trial targeting non-proliferative diabetic retinopathy, marking a significant regulatory milestone. The company also reported its Q2 2025 financial results, highlighting a decrease in net revenue due to reimbursement challenges, but an increase in DEXTENZA sales. Despite a net loss, Ocular Therapeutix maintains a strong financial position with a cash runway into 2028. The company’s strategic focus on AXPAXLI trials for wet AMD, aiming for a superiority label, has led to a price target adjustment by Scotiabank, reflecting updated timelines for trial data readouts. The firm remains optimistic about its market potential, supported by promising clinical trial progress and strategic decisions, with an upcoming Investor Day to discuss its global commercial outlook.
Spark’s Take on OCUL Stock
According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.
The overall stock score of 56 reflects significant financial challenges, with declining revenues and persistent losses being the most impactful factors. However, positive technical indicators and a promising strategic outlook from the earnings call provide some optimism. The valuation remains a concern due to the negative P/E ratio and lack of dividend yield.
To see Spark’s full report on OCUL stock, click here.
More about Ocular Therapeutix
YTD Price Performance: 40.96%
Average Trading Volume: 2,368,393
Technical Sentiment Signal: Buy
Current Market Cap: $2.14B